Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
The International Journal of Cardiovascular Imaging
Published in: The International Journal of Cardiovascular Imaging 4/2023

21-12-2022 | Cardiac Amyloidosis | Review

Role of cardiovascular magnetic resonance in the clinical evaluation of left ventricular hypertrophy: a 360° panorama

Authors: Silvia Aguiar Rosa, Boban Thomas, Maurizio Pieroni, Niccolò Maurizi, Mattia Zampieri, Francesco Cappelli, Alberto Marchi, Silvia Pradella, Nuno Cardim, Jan Bogaert, Iacopo Olivotto

Published in: The International Journal of Cardiovascular Imaging | Issue 4/2023

Login to get access

Abstract

Left ventricular hypertrophy (LVH) is a frequent imaging finding in the general population. In order to identify the precise etiology, a comprehensive diagnostic approach should be adopted, including the prevalence of each entity that may cause LVH, family history, clinical, electrocardiographic and imaging findings. By providing a detailed evaluation of the myocardium, cardiovascular magnetic resonance (CMR) has assumed a central role in the differential diagnosis of left ventricular hypertrophy, with the technique of parametric imaging allowing more refined tissue characterization. This article aims to establish a parallel between pathophysiological features and imaging findings through the broad spectrum of LVH entities, emphasizing the role of CMR in the differential diagnosis.
Appendix
Available only for authorised users
Literature
1.
Levy D (1988) Left ventricular hypertrophy: epidemiological insights from the Framingham heart study. Drugs 35(5):1–5PubMedCrossRef
2.
Armstrong AC, Gjesdal O, Almeida A, Nacif M, Wu C, Bluemke DA, Brumback LLJ (2014) Left ventricular mass and hypertrophy by echocardiography and cardiac magnetic resonance: the multi-ethnic study of atherosclerosis. Echocardiography 31(1):12–20PubMedCrossRef
3.
Bluemke DA, Kronmal RA, Lima JAC, Liu K, Olson J, Burke GL et al (2008) The relationship of left ventricular mass and geometry to incident cardiovascular events. The MESA (Multi-Ethnic Study of Atherosclerosis) study. J Am Coll Cardiol 52(25):2148–2155PubMedPubMedCentralCrossRef
4.
Gupta S, Berry JD, Ayers CR, Peshock RM, Khera A, De Lemos JA et al (2010) Left ventricular hypertrophy, aortic wall thickness, and lifetime predicted risk of cardiovascular disease: the Dallas heart study. JACC Cardiovasc Imaging 3(6):605–613PubMedCrossRef
5.
Brumback LC, Kronmal R, Heckbert SR, Ni H, Hundley WG, Lima JA et al (2010) Body size adjustments for left ventricular mass by cardiovascular magnetic resonance and their impact on left ventricular hypertrophy classification. Int J Cardiovasc Imaging 26(4):459–468PubMedPubMedCentralCrossRef
6.
Gaasch WH, Zile MR (2011) Left ventricular structural remodeling in health and disease: with special emphasis on volume, mass, and geometry. J Am Coll Cardiol 58(17):1733–1740PubMedCrossRef
7.
Finocchiaro G, Dhutia H, D’Silva A, Malhotra A, Steriotis A, Millar L et al (2017) Effect of sex and sporting discipline on LV adaptation to exercise. JACC Cardiovasc Imaging 10(9):965–972PubMedCrossRef
8.
Pelliccia A, Caselli S, Sharma S, Basso C, Bax JJ, Corrado D et al (2018) European Association of Preventive Cardiology (EAPC) and European Association of Cardiovascular Imaging (EACVI) joint position statement: recommendations for the indication and interpretation of cardiovascular imaging in the evaluation of the athlete’s he. Eur Heart J 39(21):1949–1969PubMedCrossRef
9.
Camici PG, Olivotto I, Rimoldi OE (2012) The coronary circulation and blood flow in left ventricular hypertrophy. J Mol Cell Cardiol 52(4):857–864PubMedCrossRef
10.
Olivotto I, Cecchi F, Gistri R, Lorenzoni R, Chiriatti G, Girolami F et al (2006) Relevance of coronary microvascular flow impairment to long-term remodeling and systolic dysfunction in hypertrophic cardiomyopathy. J Am Coll Cardiol 47(5):1043–1048PubMedCrossRef
11.
Nordin S, Kozor R, Medina-Menacho K, Abdel-Gadir A, Baig S, Sado DM et al (2019) Proposed stages of myocardial phenotype development in fabry disease. JACC Cardiovasc Imaging 12(8P2):1673–1683PubMedCrossRef
12.
Stokes MB, Taylor AJ, McLean CA, D’Arcy CE, Mariani JA (2016) Severe left ventricular hypertrophy and marked cardiac fibrosis in Danon disease. Int J Cardiol 221:14–16PubMedCrossRef
13.
Kramer CM, Barkhausen J, Bucciarelli-Ducci C, Flamm SD, Kim RJ, Nagel E (2020) Standardized cardiovascular magnetic resonance imaging (CMR) protocols: 2020 update. J Cardiovasc Magn Reson 22(1):1–18CrossRef
14.
Grothues F, Smith GC, Moon JCC, Bellenger NG, Collins P, Klein HU et al (2002) Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. Am J Cardiol 90(1):29–34PubMedCrossRef
15.
Kawel-Boehm N, Hetzel SJ, Ambale-Venkatesh B, Captur G, Francois CJ, Jerosch-Herold M et al (2020) Reference ranges (“normal values”) for cardiovascular magnetic resonance (CMR) in adults and children: 2020 update. J Cardiovasc Magn Reson 22(1):1–63CrossRef
16.
Petersen SE, Khanji MY, Plein S, Lancellotti P, Bucciarelli-Ducci C (2019) European Association of Cardiovascular Imaging expert consensus paper: a comprehensive review of cardiovascular magnetic resonance normal values of cardiac chamber size and aortic root in adults and recommendations for grading severity. Eur Heart J Cardiovasc Imaging 20(12):1321–1331PubMedCrossRef
17.
Messroghli DR, Moon JC, Ferreira VM, Grosse-Wortmann L, He T, Kellman P et al (2017) Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2 and extracellular volume: a consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imagin. J Cardiovasc Magn Reson 19(1):75PubMedPubMedCentralCrossRef
18.
Halliday BP, Prasad SK (2019) The interstitium in the hypertrophied heart. JACC Cardiovasc Imaging 12(11 Pt 2):2357–2368PubMedCrossRef
19.
Nakamori S, Dohi K, Ishida M, Goto Y, Imanaka-Yoshida K, Omori T et al (2018) Native T1 mapping and extracellular volume mapping for the assessment of diffuse myocardial fibrosis in dilated cardiomyopathy. JACC Cardiovasc Imaging 11(1):48–59PubMedCrossRef
20.
Robinson AA, Chow K, Salerno M (2019) Myocardial T1 and ECV measurement: underlying concepts and technical considerations. JACC Cardiovasc Imaging 12(11P2):2332–2344PubMedPubMedCentralCrossRef
21.
Iles LM, Ellims AH, Llewellyn H, Hare JL, Kaye DM, McLean CA et al (2015) Histological validation of cardiac magnetic resonance analysis of regional and diffuse interstitial myocardial fibrosis. Eur Heart J Cardiovasc Imaging 16(1):14–22PubMedCrossRef
22.
Moon JCC, Reed E, Sheppard MN, Elkington AG, Ho SY, Burke M et al (2004) The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 43(12):2260–2264PubMedCrossRef
23.
Caselli S, Maron MS, Urbano-Moral JA, Pandian NG, Maron BJ, Pelliccia A (2014) Differentiating left ventricular hypertrophy in athletes from that in patients with hypertrophic cardiomyopathy. Am J Cardiol 114(9):1383–1389PubMedCrossRef
24.
Wakatsuki T, Schlessinger J, Elson EL (2004) The biochemical response of the heart to hypertension and exercise. Trends Biochem Sci 29(11):609–617PubMedCrossRef
25.
Małek ŁA, Barczuk-Falęcka M, Werys K, Czajkowska A, Mróz A, Witek K et al (2019) Cardiovascular magnetic resonance with parametric mapping in long-term ultra-marathon runners. Eur J Radiol 117:89–94PubMedCrossRef
26.
McDiarmid AK, Swoboda PP, Erhayiem B, Lancaster RE, Lyall GK, Broadbent DA et al (2016) Athletic cardiac adaptation in males is a consequence of elevated myocyte mass. Circ Cardiovasc Imaging 9(4):e003579PubMedPubMedCentralCrossRef
27.
Pelliccia A, Maron BJ, De Luca R, Di Paolo FM, Spataro A, Culasso F (2002) Remodeling of left ventricular hypertrophy in elite athletes after long-term deconditioning. Circulation 105(8):944–949PubMedCrossRef
28.
29.
30.
31.
32.
Dávila DF, Donis JH, Odreman R, Gonzalez M, Landaeta A (2008) Patterns of left ventricular hypertrophy in essential hypertension: should echocardiography guide the pharmacological treatment? Int J Cardiol 124(2):134–138PubMedCrossRef
33.
Kuruvilla S, Janardhanan R, Antkowiak P, Keeley EC, Adenaw N, Brooks J et al (2015) Increased extracellular volume and altered mechanics are associated with LVH in hypertensive heart disease, not hypertension alone. JACC Cardiovasc Imaging 8(2):172–180PubMedPubMedCentralCrossRef
34.
Querejeta R, Varo N, López B, Larman M, Artiñano E, Etayo JC et al (2000) Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation 101(14):1729–1735PubMedCrossRef
35.
Díez J, González A, López B, Querejeta R (2005) Mechanisms of disease: pathologic structural remodeling is more than adaptive hypertrophy in hypertensive heart disease. Nat Clin Pract Cardiovasc Med 2(4):209–216PubMedCrossRef
36.
Treibel TA, Zemrak F, Sado DM, Banypersad SM, White SK, Maestrini V et al (2015) Extracellular volume quantification in isolated hypertension - changes at the detectable limits? J Cardiovasc Magn Reson 17(1):74PubMedPubMedCentralCrossRef
37.
Wang S, Hu H, Lu M, Sirajuddin A, Li J, An J et al (2017) Myocardial extracellular volume fraction quantified by cardiovascular magnetic resonance is increased in hypertension and associated with left ventricular remodeling. Eur Radiol 27(11):4620–4630PubMedCrossRef
38.
Kim J, Kochav JD, Gurevich S, Afroz A, Petashnick M, Volo S et al (2014) Left ventricular geometric remodeling in relation to non-ischemic scar pattern on cardiac magnetic resonance imaging. Int J Cardiovasc Imaging 30(8):1559–1567PubMedPubMedCentralCrossRef
39.
Rudolph A, Abdel-Aty H, Bohl S, Boyé P, Zagrosek A, Dietz R et al (2009) Noninvasive detection of fibrosis applying contrast-enhanced cardiac magnetic resonance in different forms of left ventricular hypertrophy. Relation to remodeling. J Am Coll Cardiol 53(3):284–291PubMedCrossRef
40.
Muiesan ML, Rizzoni D, Salvetti M, Porteri E, Monteduro C, Guelfi D et al (2002) Structural changes in small resistance arteries and left ventricular geometry in patients with primary and secondary hypertension. J Hypertens 20(7):1439–1444PubMedCrossRef
41.
Mahfoud F, Urban D, Teller D, Linz D, Stawowy P, Hassel JH et al (2014) Effect of renal denervation on left ventricular mass and function in patients with resistant hypertension: data from a multi-centre cardiovascular magnetic resonance imaging trial. Eur Heart J 35(33):2224–2231PubMedCrossRef
42.
Rimoldi SF, Scherrer U, Messerli FH (2014) Secondary arterial hypertension: when, who, and how to screen? Eur Heart J 35(19):1245–1254PubMedCrossRef
43.
Rossi GP, Sacchetto A, Pavan E, Palatini P, Graniero GR, Canali C et al (1997) Remodeling of the left ventricle in primary aldosteronism due to conn’s adenoma. Circulation 95(6):1471–1478PubMedCrossRef
44.
Freel EM, Mark PB, Weir RAP, McQuarrie EP, Allan K, Dargie HJ et al (2012) Demonstration of blood pressure-independent noninfarct myocardial fibrosis in primary aldosteronism: a cardiac magnetic resonance imaging study. Circ Cardiovasc Imaging 5(6):740–747PubMedCrossRef
45.
Su MYM, Wu VC, Yu HY, Lin YH, Kuo CC, Liu KL et al (2012) Contrast-enhanced MRI index of diffuse myocardial fibrosis is increased in primary aldosteronism. J Magn Reson Imaging 35(6):1349–1355PubMedCrossRef
46.
Kamenický P, Redheuil A, Roux C, Salenave S, Kachenoura N, Raissouni Z et al (2014) Cardiac structure and function in cushing’s syndrome: a cardiac magnetic resonance imaging study. J Clin Endocrinol Metab 99(11):E2144–E2153PubMedPubMedCentralCrossRef
47.
Yiu KH, Marsan NA, Delgado V, Biermasz NR, Holman ER, Smit JWA et al (2012) Increased myocardial fibrosis and left ventricular dysfunction in Cushing’s syndrome. Eur J Endocrinol 166(1):27–34PubMedCrossRef
48.
49.
Roux C, Kachenoura N, Raissuni Z, Mousseaux E, Young J, Graves MJ et al (2017) Effects of cortisol on the heart: characterization of myocardial involvement in cushing’s disease by longitudinal cardiac MRI T1 mapping. J Magn Reson Imaging 45(1):147–156PubMedCrossRef
50.
Ferreira VM, Marcelino M, Piechnik SK, Marini C, Karamitsos TD, Ntusi NAB et al (2016) Pheochromocytoma is characterized by catecholamine-mediated myocarditis, focal and diffuse myocardial fibrosis, and myocardial dysfunction. J Am Coll Cardiol 67(20):2364–2374PubMedCrossRef
51.
Iida M, Yamamoto M, Ishiguro Y, Yamazaki M, Honjo H, Kamiya K (2012) Thyroid hormone within the normal range is associated with left ventricular mass in patients with hypertension. J Am Soc Hypertens 6(4):261–269PubMedCrossRef
52.
Dörr M, Wolff B, Robinson DM, John U, Lüdemann J, Meng W et al (2005) The association of thyroid function with cardiac mass and left ventricular hypertrophy. J Clin Endocrinol Metab 90(2):673–677PubMedCrossRef
53.
Timsit J, Riou B, Bertherat J, Wisnewsky C, Kato NS, Weisberg AS et al (1990) Effects of chronic growth hormone hypersecretion on intrinsic contractility, energetics, isomyosin pattern, and myosin adenosine triphosphatase activity of rat left ventricle. J Clin Invest 86(2):507–515PubMedPubMedCentralCrossRef
54.
55.
Guo X, Cao J, Liu P, Cao Y, Li X, Gao L et al (2020) Cardiac abnormalities in acromegaly patients: a cardiac magnetic resonance study. Int J Endocrinol 2020:2018464PubMedPubMedCentralCrossRef
56.
Bogazzi F, Lombardi M, Strata E, Aquaro G, Di Bello V, Cosci C et al (2008) High prevalence of cardiac hypertophy without detectable signs of fibrosis in patients with untreated active acromegaly: an in vivo study using magnetic resonance imaging. Clin Endocrinol (Oxf) 68(3):361–368PubMedCrossRef
57.
Gouya H, Vignaux O, Le Roux P, Chanson P, Bertherat J, Bertagna X et al (2008) Rapidly reversible myocardial edema in patients with acromegaly: assessment with ultrafast T2 mapping in a single-breath-hold MRI sequence. Am J Roentgenol 190(6):1576–1582CrossRef
58.
Guo X, Cao Y, Cao J, Li X, Liu P, Wang Z et al (2020) Reversibility of cardiac involvement in acromegaly patients after surgery: 12-month follow-up using cardiovascular magnetic resonance. Front Endocrinol (Lausanne) 11:598948PubMedCrossRef
59.
Niroumand M, Kuperstein R, Sasson Z, Hanly PJ (2001) Impact of obstructive sleep apnea on left ventricular mass and diastolic function. Am J Respir Crit Care Med 163(7):1632–1636PubMedCrossRef
60.
Prisant LM, Mawulawde K, Kapoor D, Joe C (2004) Coarctation of the aorta: a secondary cause of hypertension. J Clin Hypertens (Greenwich) 6(6):347–350PubMedCrossRef
61.
Luijendijk P, Bouma BJ, Vriend JWJ, Groenink M, Spijkerboer AM, Mulder BJM (2013) Left ventricular fibrosis in adults after coarctation repair, does it play a role? Int J Cardiol 168(5):5029–5030PubMedCrossRef
62.
Devabhaktuni SR, Chakfeh E, Malik AO, Pengson JA, Rana J, Ahsan CH (2018) Subvalvular aortic stenosis: a review of current literature. Clin Cardiol 41(1):131–136PubMedPubMedCentralCrossRef
63.
Merla G, Brunetti-Pierri N, Piccolo P, Micale L, Loviglio MN (2012) Supravalvular aortic stenosis: elastin arteriopathy. Circ Cardiovasc Genet 5(6):692–696PubMedCrossRef
64.
65.
Choudhury L, Rosen SD, Patel D, Nihoyannopoulos P, Camici PG (1997) Coronary vasodilator reserve in primary and secondary left ventricular hypertrophy. A study with positron emission tomography. Eur Heart J 18(1):108–116PubMedCrossRef
66.
Hein S, Arnon E, Kostin S, Schönburg M, Elsässer A, Polyakova V et al (2003) Progression from compensated hypertrophy to failure in the pressure-overloaded human: heart structural deterioration and compensatory mechanisms. Circulation 107(7):984–991PubMedCrossRef
67.
Treibel TA, Kozor R, Fontana M, Torlasco C, Reant P, Badiani S et al (2018) Sex dimorphism in the myocardial response to aortic stenosis. JACC Cardiovasc Imaging 11(7):962–973PubMedPubMedCentralCrossRef
68.
Lee SP, Lee W, Lee JM, Park EA, Kim HK, Kim YJ et al (2015) Assessment of diffuse myocardial fibrosis by using MR imaging in asymptomatic patients with aortic stenosis. Radiology 274(2):359–369PubMedCrossRef
69.
Schelbert EB, Messroghli DR (2016) State of the art: clinical applications of cardiac T1 mapping. Radiology 278(3):658–676PubMedCrossRef
70.
Everett RJ, Treibel TA, Fukui M, Lee H, Rigolli M, Singh A et al (2020) Extracellular myocardial volume in patients with aortic stenosis. J Am Coll Cardiol 75(3):304–316PubMedPubMedCentralCrossRef
71.
Debl K, Djavidani B, Buchner S, Lipke C, Nitz W, Feuerbach S et al (2006) Delayed hyperenhancement in magnetic resonance imaging of left ventricular hypertrophy caused by aortic stenosis and hypertrophic cardiomyopathy: visualisation of focal fibrosis. Heart 92(10):1447–1451PubMedPubMedCentralCrossRef
72.
Dweck MR, Joshi S, Murigu T, Alpendurada F, Jabbour A, Melina G et al (2011) Midwall fibrosis is an independent predictor of mortality in patients with aortic stenosis. J Am Coll Cardiol 58(12):1271–1279PubMedCrossRef
73.
Weidemann F, Herrmann S, Störk S, Niemann M, Frantz S, Lange V et al (2009) Impact of myocardial fibrosis in patients with symptomatic severe aortic stenosis. Circulation 120(7):577–584PubMedCrossRef
74.
Krayenbuehl HP, Hess OM, Monrad ES, Schneider J, Mall G, Turina M (1989) Left ventricular myocardial structure in aortic valve disease before, intermediate, and late after aortic valve replacement. Circulation 79(4):744–755PubMedCrossRef
75.
Treibel TA, Kozor R, Schofield R, Benedetti G, Fontana M, Bhuva AN et al (2018) Reverse myocardial remodeling following valve replacement in patients with aortic stenosis. J Am Coll Cardiol 71(8):860–871PubMedPubMedCentralCrossRef
76.
Nitsche C, Scully PR, Patel KP, Kammerlander AA, Koschutnik M, Dona C et al (2021) Prevalence and outcomes of concomitant aortic stenosis and cardiac amyloidosis. J Am Coll Cardiol 77(2):128–139PubMedPubMedCentralCrossRef
77.
Ternacle J, Krapf L, Mothy D, Magne J, Nguyen A, Galat A et al (2019) Aortic stenosis and cardiac amyloidosis: JACC review topic of the week. J Am Coll Cardiol 74(21):2638–2651PubMedCrossRef
78.
Cavalcante JL, Rijal S, Abdelkarim I, Althouse AD, Sharbaugh MS, Fridman Y et al (2017) Cardiac amyloidosis is prevalent in older patients with aortic stenosis and carries worse prognosis. J Cardiovasc Magn Reson 19(1):98PubMedPubMedCentralCrossRef
79.
Baggiano A, Boldrini M, Martinez-Naharro A, Kotecha T, Petrie A, Rezk T et al (2020) Noncontrast magnetic resonance for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging 13(1):69–80PubMedCrossRef
80.
Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P et al (2020) 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 142(25):e533–e557
81.
Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, Hagege AA, Lafont A, Limongelli G, Mahrholdt H, McKenna WJ, Mogensen J, Nihoyannopoulos P, Nistri S, Pieper PG, Pieske B, Rapezzi C, Rutten FH, Tillmanns CWH (2014) 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 35(39):2733–2779PubMedCrossRef
82.
83.
84.
Maron MS, Maron BJ, Harrigan C, Buros J, Gibson CM, Olivotto I et al (2009) Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance. J Am Coll Cardiol 54(3):220–228PubMedCrossRef
85.
Varnava AM, Elliott PM, Sharma S, McKenna WJ, Davies MJ (2000) Hypertrophic cardiomyopathy: the interrelation of disarray, fibrosis and small vessel disease. Heart 84(5):476–482PubMedPubMedCentralCrossRef
86.
Basso C, Thiene G, Corrado D, Buja G, Melacini P, Nava A (2000) Hypertrophic cardiomyopathy and sudden death in the young: Pathologic evidence of myocardial ischemia. Hum Pathol 31(8):988–998PubMedCrossRef
87.
Maron BJ, Wolfson JK, Epstein SE, Roberts WC (1986) Intramural (“small vessel”) coronary artery disease in hypertrophic cardiomyopathy. J Am Coll Cardiol 8(3):545–557PubMedCrossRef
88.
Ismail TF, Hsu L-Y, Greve AM, Gonçalves C, Jabbour A, Gulati A et al (2014) Coronary microvascular ischemia in hypertrophic cardiomyopathy - a pixel-wise quantitative cardiovascular magnetic resonance perfusion study. J Cardiovasc Magn Reson 16(1):1–10CrossRef
89.
Villa ADM, Sammut E, Zarinabad N, Carr-White G, Lee J, Bettencourt N et al (2016) Microvascular ischemia in hypertrophic cardiomyopathy: new insights from high-resolution combined quantification of perfusion and late gadolinium enhancement. J Cardiovasc Magn Reson 18:4PubMedPubMedCentralCrossRef
90.
Petersen SE, Jerosch-Herold M, Hudsmith LE, Robson MD, Francis JM, Doll HA et al (2007) Evidence for microvascular dysfunction in hypertrophic cardiomyopathy: new insights from multiparametric magnetic resonance imaging. Circulation 115(18):2418–2425PubMedCrossRef
91.
Aguiar Rosa S, Thomas B, Fiarresga A, Papoila AL, Alves M, Pereira R et al (2021) The impact of ischemia assessed by magnetic resonance on functional, arrhythmic, and imaging features of hypertrophic cardiomyopathy. Front Cardiovasc Med 8:1–11CrossRef
92.
93.
Shirani J, Pick R, Roberts WC, Maron BJ (2000) Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. J Am Coll Cardiol 35(1):36–44PubMedCrossRef
94.
Ho CY, Abbasi SA, Neilan TG, Shah RV, Chen Y, Heydari B et al (2013) T1 measurements identify extracellular volume expansion in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy. Circ Cardiovasc Imaging 6(3):415–422PubMedPubMedCentralCrossRef
95.
Ellims AH, Iles LM, Ling LH, Chong B, Macciocca I, Slavin GS et al (2014) A comprehensive evaluation of myocardial fibrosis in hypertrophic cardio myopathy with cardiacmagnetic resonance imaging: linking genotype with fibrotic phenotype. Eur Heart J Cardiovasc Imaging 15(10):1108–1116PubMedCrossRef
96.
Chan RH, Maron BJ, Olivotto I, Pencina MJ, Assenza GE, Haas T et al (2014) Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation 130(6):484–495PubMedCrossRef
97.
Todiere G, Pisciella L, Barison A, Del Franco A, Zachara E, Piaggi P et al (2014) Abnormal T2-STIR magnetic resonance in hypertrophic cardiomyopathy: a marker of advanced disease and electrical myocardial instability. PLoS ONE 9(10):e111366PubMedPubMedCentralCrossRef
98.
Ariga R, Tunnicliffe EM, Manohar SG, Mahmod M, Raman B, Piechnik SK et al (2019) Identification of myocardial disarray in patients with hypertrophic cardiomyopathy and ventricular arrhythmias. J Am Coll Cardiol 73(20):2493–2502PubMedPubMedCentralCrossRef
99.
Ferreira PF, Kilner PJ, Mcgill LA, Nielles-Vallespin S, Scott AD, Ho SY et al (2014) In vivo cardiovascular magnetic resonance diffusion tensor imaging shows evidence of abnormal myocardial laminar orientations and mobility in hypertrophic cardiomyopathy. J Cardiovasc Magn Reson 16(1):1–16CrossRef
100.
Quarta G, Aquaro GD, Pedrotti P, Pontone G, Dellegrottaglie S, Iacovoni A et al (2018) Cardiovascular magnetic resonance imaging in hypertrophic cardiomyopathy: the importance of clinical context. Eur Heart J Cardiovasc Imaging 19(6):601–610PubMedCrossRef
101.
Kozor R, Callaghan F, Tchan M, Hamilton-Craig C, Figtree GA, Grieve SM (2015) A disproportionate contribution of papillary muscles and trabeculations to total left ventricular mass makes choice of cardiovascular magnetic resonance analysis technique critical in Fabry disease. J Cardiovasc Magn Reson 17(1):22PubMedPubMedCentralCrossRef
102.
Niemann M, Liu D, Hu K, Herrmann S, Breunig F, Strotmann J et al (2011) Prominent papillary muscles in fabry disease: a diagnostic marker? Ultrasound Med Biol 37(1):37–43PubMedCrossRef
103.
Brakch N, Dormond O, Bekri S, Golshayan D, Correvon M, Mazzolai L et al (2010) Evidence for a role of sphingosine-1 phosphate in cardiovascular remodelling in Fabry disease. Eur Heart J 31(1):67–76PubMedCrossRef
104.
Barbey F, Brakch N, Linhart A, Rosenblatt-Velin N, Jeanrenaud X, Qanadli S et al (2006) Cardiac and vascular hypertrophy in Fabry disease: evidence for a new mechanism independent of blood pressure and glycosphingolipid deposition. Arterioscler Thromb Vasc Biol 26(4):839–844PubMedCrossRef
105.
Pieroni M, Moon JC, Arbustini E, Barriales-Villa R, Camporeale A, Vujkovac AC et al (2021) Cardiac involvement in fabry disease: JACC review topic of the week. J Am Coll Cardiol 77(7):922–936PubMedCrossRef
106.
Nordin S, Kozor R, Vijapurapu R, Augusto JB, Knott KD, Captur G et al (2019) Myocardial storage, inflammation, and cardiac phenotype in fabry disease after one year of enzyme replacement therapy. Circ Cardiovasc Imaging 12(12):1–9CrossRef
107.
Imbriaco M, Pisani A, Spinelli L, Cuocolo A, Messalli G, Capuano E et al (2009) Effects of enzyme-replacement therapy in patients with Anderson-Fabry disease: a prospective longterm cardiac magnetic resonance imaging study. Heart 95(13):1103–1107PubMedCrossRef
108.
Messalli G, Imbriaco M, Avitabile G, Russo R, Iodice D, Spinelli L et al (2012) Role of cardiac MRI in evaluating patients with Anderson-Fabry disease: assessing cardiac effects of long-term enzyme replacement therapy. Radiol Med 117(1):19–28PubMedCrossRef
109.
Thompson RB, Chow K, Khan A, Chan A, Shanks M, Paterson I et al (2013) T1 mapping with cardiovascular MRI is highly sensitive for fabry disease independent of hypertrophy and sex. Circ Cardiovasc Imaging 6(5):637–645PubMedCrossRef
110.
Sado DM, Flett AS, Banypersad SM, White SK, Maestrini V, Quarta G et al (2012) Cardiovascular magnetic resonance measurement of myocardial extracellular volume in health and disease. Heart 98(19):1436–1441PubMedCrossRef
111.
Nordin S, Kozor R, Bulluck H, Castelletti S, Rosmini S, Abdel-Gadir A et al (2016) Cardiac fabry disease with late gadolinium enhancement is a chronic inflammatory cardiomyopathy. J Am Coll Cardiol 68(15):1707–1708PubMedCrossRef
112.
Weidemann F, Störk S, Liu D, Hu K, Herrmann S, Ertl G et al (2013) Cardiomyopathy of Friedreich ataxia. J Neurochem 126(SUPPL 1):88–93PubMedCrossRef
113.
Rajagopalan B, Francis JM, Cooke F, Korlipara LVP, Blamire AM, Schapira AHV et al (2010) Analysis of the factors influencing the cardiac phenotype in Friedreich’s ataxia. Mov Disord 25(7):846–852PubMedCrossRef
114.
Koeppen AH, Ramirez RL, Becker AB, Bjork ST, Levi S, Santambrogio P et al (2015) The pathogenesis of cardiomyopathy in Friedreich ataxia. PLoS ONE 10(3):e0116396PubMedPubMedCentralCrossRef
115.
Campuzano V, Montermini L, Moltò MD, Pianese L, Cossée M, Cavalcanti F et al (1996) Friedreich’s ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science (80-) 271(5254):1423–1427CrossRef
116.
Bradley JL, Blake JC, Chamberlain S, Thomas PK, Cooper JM, Schapira AHV (2000) Clinical, biochemical and molecular genetic correlations in Friedreich’s ataxia. Hum Mol Genet 9(2):275–282PubMedCrossRef
117.
Michael S, Petrocine SV, Qian J, Lamarche JB, Knutson MD, Garrick MD et al (2006) Iron and iron-responsive proteins in the cardiomyopathy of Friedreich’s ataxia. Cerebellum 5(4):257–267PubMedCrossRef
118.
Mavrogeni S, Giannakopoulou A, Katsalouli M, Pons RM, Papavasiliou A, Kolovou G et al (2020) Friedreich’s Ataxia: case series and the additive value of cardiovascular magnetic resonance. J Neuromuscul Dis 7(1):61–67PubMedCrossRef
119.
Mehta N, Chacko P, Jin J, Tran T, Prior TW, He X et al (2016) Serum versus imaging biomarkers in Friedreich ataxia to indicate left ventricular remodeling and outcomes. Texas Hear Inst J 43(4):305–310CrossRef
120.
Calcagni G, Adorisio R, Martinelli S, Grutter G, Baban A, Versacci P et al (2018) Clinical presentation and natural history of hypertrophic cardiomyopathy in RASopathies. Heart Fail Clin 14(2):225–235PubMedCrossRef
121.
Limongelli G, Pacileo G, Marino B, Digilio MC, Sarkozy A, Elliott P et al (2007) Prevalence and clinical significance of cardiovascular abnormalities in patients with the LEOPARD syndrome. Am J Cardiol 100(4):736–741PubMedCrossRef
122.
Bates MGD, Bourke JP, Giordano C, D’Amati G, Turnbull DM, Taylor RW (2012) Cardiac involvement in mitochondrial DNA disease: clinical spectrum, diagnosis, and management. Eur Heart J 33(24):3023–3033PubMedPubMedCentralCrossRef
123.
Hsu YHR, Yogasundaram H, Parajuli N, Valtuille L, Sergi C, Oudit GY (2016) MELAS syndrome and cardiomyopathy: linking mitochondrial function to heart failure pathogenesis. Heart Fail Rev 21(1):103–116PubMedCrossRef
124.
Meyers DE, Basha HI, Koenig MK (2013) Mitochondrial cardiomyopathy: pathophysiology, diagnosis, and management. Texas Heart Inst J 40:385
125.
Florian A, Ludwig A, Stubbe-Dräger B, Boentert M, Young P, Waltenberger J et al (2015) Characteristic cardiac phenotypes are detected by cardiovascular magnetic resonance in patients with different clinical phenotypes and genotypes of mitochondrial myopathy. J Cardiovasc Magn Reson 17(1):1–11CrossRef
126.
Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS (2019) Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol 73(22):2872–2891PubMedPubMedCentralCrossRef
127.
Gertz MA, Benson MD, Dyck PJ, Grogan M, Coelho T, Cruz M et al (2015) Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol 66(21):2451–2466PubMedCrossRef
128.
Falk RH, Alexander KM, Liao R, Dorbala S (2016) AL (Light-Chain) cardiac amyloidosis: a review of diagnosis and therapy. J Am Coll Cardiol 68(12):1323–1341PubMedCrossRef
129.
Kotecha T, Martinez-Naharro A, Treibel TA, Francis R, Nordin S, Abdel-Gadir A et al (2018) Myocardial edema and prognosis in amyloidosis. J Am Coll Cardiol 71(25):2919–2931PubMedCrossRef
130.
Fontana M, Banypersad SM, Treibel TA, Maestrini V, Sado DM, White SK et al (2014) Native T1 mapping in transthyretin amyloidosis. JACC Cardiovasc Imaging 7(2):157–165PubMedCrossRef
131.
Robbers LFHJ, Baars EN, Brouwer WP, Beek AM, Hofman MBM, Niessen HWM et al (2012) T1 mapping shows increased extracellular matrix size in the myocardium due to amyloid depositions. Circ Cardiovasc Imaging 5(3):423–426PubMedCrossRef
132.
Pan JA, Kerwin MJ, Salerno M (2020) Native T1 mapping, extracellular volume mapping, and late gadolinium enhancement in cardiac amyloidosis: a meta-analysis. JACC Cardiovasc Imaging 13(6):1299–1310PubMedPubMedCentralCrossRef
133.
Dungu JN, Valencia O, Pinney JH, Gibbs SDJ, Rowczenio D, Gilbertson JA et al (2014) CMR-based differentiation of AL and ATTR cardiac amyloidosis. JACC Cardiovasc Imaging 7(2):133–142PubMedCrossRef
134.
Fontana M, Pica S, Reant P, Abdel-Gadir A, Treibel TA, Banypersad SM et al (2015) Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 132(16):1570–1579PubMedPubMedCentralCrossRef
135.
Chatzantonis G, Bietenbeck M, Elsanhoury A, Tschöpe C, Pieske B, Tauscher G et al (2021) Diagnostic value of cardiovascular magnetic resonance in comparison to endomyocardial biopsy in cardiac amyloidosis: a multi-centre study. Clin Res Cardiol 110(4):555–568PubMedCrossRef
136.
Ammirati E, Frigerio M, Adler ED, Basso C, Birnie DH, Brambatti M et al (2020) Management of acute myocarditis and chronic inflammatory cardiomyopathy: an expert consensus document. Circ Heart Fail 13:663–687CrossRef
137.
Kociol RD, Cooper LT, Fang JC, Moslehi JJ, Pang PS, Sabe MA et al (2020) Recognition and initial management of fulminant myocarditis: a scientific statement from the American Heart Association. Circulation 141:E69-92PubMedCrossRef
138.
Ferreira VM, Schulz-Menger J, Holmvang G, Kramer CM, Carbone I, Sechtem U et al (2018) Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations. J Am Coll Cardiol 72(24):3158–3176PubMedCrossRef
139.
Brunner-La Rocca HP, Sütsch G, Schneider J, Follath F, Kiowski W (1996) Natural course of moderate cardiac allograft rejection (Internal Society for Heart Transplantation Grade 2) early and late after transplantation. Circulation 94(6):1334–1338PubMedCrossRef
140.
Dolan RS, Rahsepar AA, Blaisdell J, Suwa K, Ghafourian K, Wilcox JE et al (2019) Multiparametric cardiac magnetic resonance imaging can detect acute cardiac allograft rejection after heart transplantation. JACC Cardiovasc Imaging 12(8P2):1632–1641PubMedPubMedCentralCrossRef
141.
Herskowitz A, Soule LM, David Mellits E, Traill TA, Achuff SC, Reitz BA et al (1987) Histologic predictors of acute cardiac rejection in human endomyocardial biopsies: a multivariate analysis. J Am Coll Cardiol 9(4):802–810PubMedCrossRef
142.
Imran M, Wang L, McCrohon J, Yu C, Holloway C, Otton J et al (2019) Native T1 mapping in the diagnosis of cardiac allograft rejection: a prospective histologically validated study. JACC Cardiovasc Imaging 12(82):1618–1628PubMedCrossRef
143.
Anthony C, Imran M, Pouliopoulos J, Emmanuel S, Iliff J, Liu Z et al (2022) Cardiovascular magnetic resonance for rejection surveillance after cardiac transplantation. Circulation 145(25):1811–1824PubMedCrossRef
Metadata
Title
Role of cardiovascular magnetic resonance in the clinical evaluation of left ventricular hypertrophy: a 360° panorama
Authors
Silvia Aguiar Rosa
Boban Thomas
Maurizio Pieroni
Niccolò Maurizi
Mattia Zampieri
Francesco Cappelli
Alberto Marchi
Silvia Pradella
Nuno Cardim
Jan Bogaert
Iacopo Olivotto
Publication date
21-12-2022
Publisher
Springer Netherlands
Published in
The International Journal of Cardiovascular Imaging / Issue 4/2023
Print ISSN: 1569-5794
Electronic ISSN: 1875-8312
DOI
https://doi.org/10.1007/s10554-022-02774-x

Other articles of this Issue 4/2023

The International Journal of Cardiovascular Imaging 4/2023 Go to the issue

OriginalPaper

Comparison of the prognostic value of lateral versus septal early mitral annulus velocity in patients with acute decompensated heart failure

Originalpaper

Transthoracic echocardiographic assessment of cardiac valves in patients with Behçet’s disease

Abstract

NASCI young investigator awards 2022

Original Paper

Automated tissue Doppler imaging for identification of occluded coronary artery in patients with suspected non-ST-elevation myocardial infarction

Original Paper

Serial changes of right ventricular function assessed by three-dimensional speckle-tracking echocardiography in clinically well adult heart transplantation patients

Original Paper

Sex-specific features of optical coherence tomography detected plaque vulnerability related to clinical outcomes: insights from the CLIMA study

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits